ScreenerHero
XBRANEXbrane Biopharma AB (publ)
STO · SE · Healthcare · Biotechnology · xbrane.com
9.500SEK-0.63%Mkt Cap: 18.72M $P/E: —

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap18.72M $
Enterprise Value20.20M $
Revenue (TTM)7.97M $
Gross Profit8.57M $
Net Income (TTM)12.17M $
Revenue/Share0.3866 USD
Last Price9.500 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0007789409
Valuation
P/E (Trailing)—
P/E (Forward)480.00
PEG—
EV/EBITDA-3.44
EV/Revenue2.54
P/S2.37
P/B0.35
EPS (TTM)-3.98
EPS (Forward)0.02
52W Range
5.42113% of range37.65
52W High37.65 SEK
52W Low5.421 SEK
Profitability
Gross Margin58.76%
Oper. Margin-5.99%
EBITDA Margin-73.64%
Profit Margin83.49%
ROE22.70%
ROA18.95%
Growth
Revenue Growth17.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.98M $
CapEx (TTM)13.36M $
FCF Margin-229.42%
FCF Yield-97.62%
Net Debt1.36M $
Net Debt/EBITDA-0.23
Balance Sheet
Debt/Equity0.10
Current Ratio3.19
Quick Ratio0.71
Book Value/Sh27.21 SEK
Cash/Share2.402 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateOct 17, 2025
Analyst Consensus
Rating—
Target (Mean)15.00 SEK
Upside (mean)+57.9%
Target Range15.00 SEK – 15.00 SEK
# Analysts1
Ownership
Shares Out.20.61M
Float15.03M
Insiders39.62%
Institutions9.25%
Technical
SMA 5010.34 (-8.1%)
SMA 2009.630 (-1.3%)
Beta0.85
S&P 52W Chg18.16%
Avg Vol (30d)19.38K
Avg Vol (10d)26.97K
Technical Indicators
RSI (14)39.7
MACD-0.2066
MACD Signal-0.1677
MACD Hist.-0.0389
BB Upper10.56 SEK
BB Middle10.01 SEK
BB Lower9.456 SEK
BB Width11.07%
ATR (14)0.4907 SEK
Vol Ratio (20d)1.51x